Loading stock data…
Harvard Bioscience, Inc. (HBIO)
$7.95-0.07 (-0.87%)
Market ClosedLast close Sep 8
Harvard Bioscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Harvard Bioscience, Inc. in the Healthcare sector is trading at $7.95 with a market capitalization of $30M. Wall Street consensus targets $7.50 (1 analysts), implying a -5.7% move over the next 12 months. The stock is currently 15% below its 52-week high of $9.40, remaining 28.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -5.7% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.75M↓ | $23.73M↑ | $20.59M↑ | $20.45M↓ | $21.77M |
| Gross Profit | $12.24M↓ | $14.17M↑ | $12.02M↑ | $11.53M↓ | $12.18M |
| Operating Income | -$939,000↓ | $1.93M↑ | $245,000↑ | -$619,000↑ | -$1.45M |
| Net Income | -$3.42M↓ | -$2.85M↓ | -$1.23M↑ | -$2.28M↑ | -$50.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular techn...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-97.39%
Volume
Today's trading volume
12,312
Recent News
Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript
CRO demand drove 11% revenue growth, though margin pressures from China sales tempered gains.
Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary
Moby summary of Harvard Bioscience, Inc.'s Q2 2026 earnings call
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ...
Strong Q2 performance driven by robust demand in China and new product adoption, prompting an upward revision to full-year revenue growth outlook.
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance
Harvard Bioscience Inc. (NASDAQ:HBIO) reported better-than-expected second-quarter results on Tuesday and raised its full-year 2026 revenue outlook after stronger demand across its telemetry and cellular and molecular technology businesses.
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New ...
Despite a slight dip in revenue, Harvard Bioscience Inc (HBIO) sees promising growth in new product lines and strategic initiatives.